Mona Hoysaeter Fenstad

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

H. Nahi, A. Waage, M. Hansson, 2020 .